NRXCF - NeutriSci International Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0447
0.0000 (0.00%)
At close: 3:56PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.0447
Open0.0447
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0447 - 0.0447
52 Week Range0.0100 - 0.0609
Volume175
Avg. Volume7,384
Market Cap6.287M
Beta (5Y Monthly)2.74
PE Ratio (TTM)N/A
EPS (TTM)-0.0170
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • ACCESSWIRE

      Distribution of NeutriSci's THC/CBD Products to Commence in California

      VANCOUVER, BC / ACCESSWIRE / March 13, 2020 / NeutriSci International Inc. ("NeutriSci" or the "Company") (NRXCF)(NU.V)(1N9.F) is pleased to announce that Cryopharm Corp. ("Cryopharm"), its US manufacturing and distribution partner, is completing the packaging of NeutriSci and Cryopharm's CBD/THC products in preparation for initial distribution to more than 90 dispensaries across the state of California, with the distribution network expected to grow to over 350 dispensaries in Q2/2020. NeutriSci's core ingredients form the basis of Marbl Melts™, which contain a clinically tested dosage providing on-set in as little as 12 minutes; compared to traditional cannabinoid infusion methods that often have incorrect dosages while potentially taking up to 120 minutes to become active. NeutriSci's Zenstix™ and Dablets™: quick melting tabs that activate faster when compared to other cannabis edibles with a powerful 10mg dose.

    • ACCESSWIRE

      NeutriSci Closes $518,000 Financing

      VANCOUVER, BC / ACCESSWIRE / March 5, 2020 / NeutriSci International Inc. ("NeutriSci" or the "Company") (NU.V)(NRXCF)(1N9.F) the innovator and pioneer behind neuenergy® is pleased to announce that it has closed on the final tranche of its non-brokered private placement (the "Placement") announced on January 16, 2020 and February 18, 2020, in which it raised proceeds of $518,000. Each Unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder to acquire an additional common share of the Company at a price of $0.05 until September 5, 2021. In connection with this tranche of the Placement, the Company paid a finder's fee of $700.

    • ACCESSWIRE

      NeutriSci Increases Financing To $1.15 Million

      VANCOUVER, BC / ACCESSWIRE / February 18, 2020 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V:NU, OTCQB:NRXCF, FRANKFURT:1N9) the innovator and pioneer behind neuenergy® is pleased to announce that it has elected to increase the size of the non-brokered private placement (the "Placement") originally announced on January 16, 2020. On January 24, 2020, the Company closed on the first tranche of the Placement, in which it raised proceeds of $655,000. Due to increased investor demand, the Company now intends to raise up to an additional $495,000 (the "Second Tranche") through the issuance of up to 9,900,000 units (the "Units") of the Company at a price of $0.05 per Unit.

    • ACCESSWIRE

      NeutriSci Closes $655,000 Financing

      VANCOUVER, BC / ACCESSWIRE / January 24, 2020 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V:NU, OTCQB:NRXCF, FRANKFURT:1N9) the innovator and pioneer behind neuenergy® is pleased to announce that it has closed on the first tranche of its non-brokered private placement (the "Placement") announced on January 16, 2020, in which it raised proceeds of $655,000. Each Unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder to acquire an additional common share of the Company at a price of $0.05 until July 24, 2021. All securities issued in connection with this tranche of the Placement are subject to a hold period expiring May 25, 2020.

    • ACCESSWIRE

      NeutriSci Withdraws Share Consolidation and Plans $0.05 Private Placement Financing

      VANCOUVER, BC / ACCESSWIRE / January 16, 2020 / NeutriSci International Inc. ("NeutriSci" or the "Company") (NU.V)(NRXCF), (1N9.F) the innovator and pioneer behind neuenergy® is pleased to announce that it will not be proceeding with the proposed financing or consolidation as announced on December 18, 2019. The Company will instead complete a non-brokered private placement offering (the "Offering"), of units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of up to $725,000. Subscriptions to the financing have been received and closing of an initial tranche is expected shortly.

    • The NeutriSci International (CVE:NU) Share Price Is Down 76% So Some Shareholders Are Rather Upset
      Simply Wall St.

      The NeutriSci International (CVE:NU) Share Price Is Down 76% So Some Shareholders Are Rather Upset

      It's not a secret that every investor will make bad investments, from time to time. But it would be foolish to simply...

    • GlobeNewswire

      NeutriSci Expands Partnership With Cryopharm and Nutritional High

      Under the expanded terms, in addition to manufacturing its own product, Marbl Melts™, Cryopharm will also manufacture NeutriSci’s ZenStix™ and Dablets™ utilizing its manufacturing and infusion license at its manufacturing facility in Sacramento, California. Ryan Erving, COO of Cryopharm commented, “We are excited to partner with NeutriSci and Nutritional High for the production and sale of our Marbl Melts, and the Dablet and Zenstix line of products.

    • GlobeNewswire

      NeutriSci Announces Initial Order From Cryopharm

      NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, is pleased to announce that it has received an initial order from Cryopharm Corporation (“Cryopharm”). NeutriSci licensed its Cryolization technology to Cryopharm for the manufacturing and distribution of buccal and sublingual rapid release consumable products utilizing both CBD and THC molecules.  Cryopharm has placed its order for NeutriSci’s core ingredients, which form the basis of the company’s Marbl Melts.  In addition to purchasing the core ingredients from NeutriSci, under the licensing terms, Cryopharm will pay NeutriSci a license fee, and a royalty on gross sales.